Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results

Arrowhead Pharmaceuticals (NASDAQ:ARWR) issued its earnings results on Thursday. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.18, FiscalAI reports. Arrowhead Pharmaceuticals had a negative return on equity of 56.92% and a negative net margin of 48.38%.The firm had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period last year, the company earned $2.75 earnings per share. The firm’s revenue for the quarter was down 86.4% on a year-over-year basis.

Here are the key takeaways from Arrowhead Pharmaceuticals’ conference call:

• REDEMPLO launch is outperforming expectations with >400 prescriptions written (~30 new scripts/week, >10% switches), accelerating refills, positive payer interactions, a U.S. WAC of $45,000/year, and regulatory approvals in Canada, China, Australia plus a CHMP positive opinion for the EU.
• Several high?impact clinical catalysts are imminent — top?line Q3 readouts for SHASTA?3/4 and MUIR?3 (plozasiran SHTG) to support an sNDA, first clinical data for ARO?DIMER?PA in Q3, and initial ARO?MAPT CNS platform data end?Q3/early?Q4, with additional ARO?INHBE/ARO?ALK7 updates in H2 2026.
• Financial and business?development moves strengthen optionality — concurrent financings ($700M convertible notes + $230M equity) plus other inflows left Arrowhead with nearly $1.8 billion in cash/investments, and the ARO?PNPLA3 license to Madrigal provides $25M upfront and up to $975M in milestones plus royalties.
• Q2 results show a net loss of $132.7M (vs prior?year quarter that included a one?time Sarepta gain), operating expenses of ~ $215M and only about $1M of derived net product sales, reflecting heavy ongoing R&D and commercialization spending.

Arrowhead Pharmaceuticals Trading Down 6.7%

Shares of NASDAQ ARWR traded down $5.26 during mid-day trading on Friday, hitting $72.70. 2,699,845 shares of the company traded hands, compared to its average volume of 1,838,659. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals has a 1 year low of $12.89 and a 1 year high of $79.48. The stock has a market capitalization of $10.18 billion, a price-to-earnings ratio of -33.81 and a beta of 1.28. The business has a 50 day moving average of $64.30 and a two-hundred day moving average of $60.36.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ARWR. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They issued an “overweight” rating and a $88.00 price objective on the stock. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday. Finally, Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $84.90.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the transaction, the insider owned 226,958 shares in the company, valued at approximately $17,021,850. The trade was a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 33,095 shares of company stock valued at $2,326,228. 3.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. EntryPoint Capital LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $329,000. Marex Group plc acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $311,000. Teza Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $300,000. Graham Capital Management L.P. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $279,000. Finally, Ieq Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $275,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.